Although anti-tumor necrosis factor (TNF) therapy has revo-lutionised the management of spondyloarthritis (SpA), 20–30% of SpA patients discontinue biological treatment because they fail to respond or their response is inadequate, and 10–20% stop because of a lack or loss of efficacy or the onset of adverse events. Published data show that anti-TNF drugs in are highly effective in patients with ankylosing spondylitis, and associated with a higher drug persistence rate. Furthermore, studies suggest considering a switch to another anti-TNF drug if a first anti-TNF agent is discontinued because of loss of efficacy or adverse events.
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure / M. Benucci, A. Damiani, F. Bandinelli, V. Grossi, M. Infantino, M. Manfredi, F.L. Gobbi, P. Sarzi-Puttini, F. Atzeni. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 20:2(2018 Feb), pp. 119-122.
|Titolo:||Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure|
|Parole Chiave:||ankylosing spondylitis (AS); anti-tumor necrosis factor (anti-TNF) drugs; efficacy; adverse events|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||feb-2018|
|Appare nelle tipologie:||01 - Articolo su periodico|